Lv3
250 积分 2024-01-03 加入
Phase to Phase: Navigating Drug Combinations with Hypomethylating Agents in Higher-risk MDS Trials for Optimal Outcomes
3天前
已完结
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
9天前
已完结
A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia
9天前
已关闭
A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia
9天前
已关闭
Iron overload in myelodysplastic syndromes (MDS)
9天前
已完结
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes
9天前
已完结
[Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]
9天前
已关闭
Turning a blind eye to deferasirox's toxicity?
9天前
已完结
Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study
9天前
已完结
皖公网安备34019202002308
